334 related articles for article (PubMed ID: 19516252)
1. Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.
Gaisler-Salomon I; Miller GM; Chuhma N; Lee S; Zhang H; Ghoddoussi F; Lewandowski N; Fairhurst S; Wang Y; Conjard-Duplany A; Masson J; Balsam P; Hen R; Arancio O; Galloway MP; Moore HM; Small SA; Rayport S
Neuropsychopharmacology; 2009 Sep; 34(10):2305-22. PubMed ID: 19516252
[TBL] [Abstract][Full Text] [Related]
2. Synaptic underpinnings of altered hippocampal function in glutaminase-deficient mice during maturation.
Gaisler-Salomon I; Wang Y; Chuhma N; Zhang H; Golumbic YN; Mihali A; Arancio O; Sibille E; Rayport S
Hippocampus; 2012 May; 22(5):1027-39. PubMed ID: 22431402
[TBL] [Abstract][Full Text] [Related]
3. GLS1 Mutant Mice Display Moderate Alterations of Hippocampal Glutamatergic Neurotransmission Associated with Specific Adaptive Behavioral Changes.
Dutar P; Tolle V; Kervern M; Carcenac C; Carola V; Gross C; Savasta M; Darmon M; Masson J
Neuroscience; 2019 Jan; 396():175-186. PubMed ID: 30472430
[TBL] [Abstract][Full Text] [Related]
4. Glutamate Dehydrogenase-Deficient Mice Display Schizophrenia-Like Behavioral Abnormalities and CA1-Specific Hippocampal Dysfunction.
Lander SS; Khan U; Lewandowski N; Chakraborty D; Provenzano FA; Mingote S; Chornyy S; Frigerio F; Maechler P; Kaphzan H; Small SA; Rayport S; Gaisler-Salomon I
Schizophr Bull; 2019 Jan; 45(1):127-137. PubMed ID: 29471549
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase activity in GLS1 Het mouse brain compared to putative pharmacological inhibition by ebselen using ex vivo MRS.
Kosten L; Chowdhury GMI; Mingote S; Staelens S; Rothman DL; Behar KL; Rayport S
Neurochem Int; 2019 Oct; 129():104508. PubMed ID: 31326460
[TBL] [Abstract][Full Text] [Related]
6. Dopamine neuron dependent behaviors mediated by glutamate cotransmission.
Mingote S; Chuhma N; Kalmbach A; Thomsen GM; Wang Y; Mihali A; Sferrazza C; Zucker-Scharff I; Siena AC; Welch MG; Lizardi-Ortiz J; Sulzer D; Moore H; Gaisler-Salomon I; Rayport S
Elife; 2017 Jul; 6():. PubMed ID: 28703706
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia.
Guo X; Hamilton PJ; Reish NJ; Sweatt JD; Miller CA; Rumbaugh G
Neuropsychopharmacology; 2009 Jun; 34(7):1659-72. PubMed ID: 19145222
[TBL] [Abstract][Full Text] [Related]
8. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior.
Basu AC; Tsai GE; Ma CL; Ehmsen JT; Mustafa AK; Han L; Jiang ZI; Benneyworth MA; Froimowitz MP; Lange N; Snyder SH; Bergeron R; Coyle JT
Mol Psychiatry; 2009 Jul; 14(7):719-27. PubMed ID: 19065142
[TBL] [Abstract][Full Text] [Related]
9. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens.
Razoux F; Garcia R; Léna I
Neuropsychopharmacology; 2007 Mar; 32(3):719-27. PubMed ID: 16525415
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Depoortère R; Dargazanli G; Estenne-Bouhtou G; Coste A; Lanneau C; Desvignes C; Poncelet M; Heaulme M; Santucci V; Decobert M; Cudennec A; Voltz C; Boulay D; Terranova JP; Stemmelin J; Roger P; Marabout B; Sevrin M; Vigé X; Biton B; Steinberg R; Françon D; Alonso R; Avenet P; Oury-Donat F; Perrault G; Griebel G; George P; Soubrié P; Scatton B
Neuropsychopharmacology; 2005 Nov; 30(11):1963-85. PubMed ID: 15956994
[TBL] [Abstract][Full Text] [Related]
11. Genetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice.
Mingote S; Masson J; Gellman C; Thomsen GM; Lin CS; Merker RJ; Gaisler-Salomon I; Wang Y; Ernst R; Hen R; Rayport S
Front Syst Neurosci; 2015; 9():165. PubMed ID: 26778975
[TBL] [Abstract][Full Text] [Related]
12. 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat.
Pietraszek M; Michaluk J; Romańska I; Wasik A; Gołembiowska K; Antkiewicz-Michaluk L
Neurotox Res; 2009 Nov; 16(4):390-407. PubMed ID: 19649683
[TBL] [Abstract][Full Text] [Related]
13. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice.
Brody SA; Geyer MA; Large CH
Psychopharmacology (Berl); 2003 Sep; 169(3-4):240-6. PubMed ID: 12698229
[TBL] [Abstract][Full Text] [Related]
14. Mice lacking brain/kidney phosphate-activated glutaminase have impaired glutamatergic synaptic transmission, altered breathing, disorganized goal-directed behavior and die shortly after birth.
Masson J; Darmon M; Conjard A; Chuhma N; Ropert N; Thoby-Brisson M; Foutz AS; Parrot S; Miller GM; Jorisch R; Polan J; Hamon M; Hen R; Rayport S
J Neurosci; 2006 Apr; 26(17):4660-71. PubMed ID: 16641247
[TBL] [Abstract][Full Text] [Related]
15. Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivo.
Öngür D; Haddad S; Prescot AP; Jensen JE; Siburian R; Cohen BM; Renshaw PF; Smoller JW
Biol Psychiatry; 2011 Jul; 70(2):169-74. PubMed ID: 21457947
[TBL] [Abstract][Full Text] [Related]
16. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs.
Yee BK; Singer P; Chen JF; Feldon J; Boison D
Eur J Neurosci; 2007 Dec; 26(11):3237-52. PubMed ID: 18005073
[TBL] [Abstract][Full Text] [Related]
17. Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes.
Willi R; Weinmann O; Winter C; Klein J; Sohr R; Schnell L; Yee BK; Feldon J; Schwab ME
J Neurosci; 2010 Jan; 30(2):556-67. PubMed ID: 20071518
[TBL] [Abstract][Full Text] [Related]
18. Neuregulin 1 Prevents Phencyclidine-Induced Behavioral Impairments and Disruptions to GABAergic Signaling in Mice.
Engel M; Snikeris P; Jenner A; Karl T; Huang XF; Frank E
Int J Neuropsychopharmacol; 2015 May; 18(7):pyu114. PubMed ID: 26478928
[TBL] [Abstract][Full Text] [Related]
19. How high-resolution basal-state functional imaging can guide the development of new pharmacotherapies for schizophrenia.
Gaisler-Salomon I; Schobel SA; Small SA; Rayport S
Schizophr Bull; 2009 Nov; 35(6):1037-44. PubMed ID: 19828591
[TBL] [Abstract][Full Text] [Related]
20. Glutamate Decarboxylase 67 Deficiency in a Subset of GABAergic Neurons Induces Schizophrenia-Related Phenotypes.
Fujihara K; Miwa H; Kakizaki T; Kaneko R; Mikuni M; Tanahira C; Tamamaki N; Yanagawa Y
Neuropsychopharmacology; 2015 Sep; 40(10):2475-86. PubMed ID: 25904362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
